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Abstract The enzyme aldose reductase (AR) is a member of aldo-
ketoreductase super-family which catalyzes the formation of sorbitol from 
glucose through polyol pathway of glucose catabolism. Reduced sorbitol 
production via polyol pathway due to AR inhibition is a target of choice for 
controlling major complications of diabetes. Epalrestat is the only commercially 
available inhibitor of AR till date,thus, there is a great need to search for 
more economical, nontoxic and safer inhibitors of AR enzyme. Flavonoids, 
the polyphenol compounds in plants have been reported for inhibitory effects 
against AR. The objective of this study is to explore the binding modes of natural 
phenolic compounds with AR to design safer natural drugs as alternatives to 
synthetic drugs. We conducted a molecular docking study on some natural 
phenolic compounds with AR enzyme in complex with the synthetic inhibitor.
The overlay of the docked pose of the selected natural phenols with the AR-
reference inhibitor complex showed that the selected natural compounds have 
the similar binding pattern with the active site residues of the enzyme as that 
of co-crystallized inhibitor. The results of docking study showed the best 
binding affinity of AR with that of 2-(4-hydroxy-3-methoxyphenyl) ethanoic 
acid and butein, having the lowest binding free energy of –9.8 kcal/mol and 
–9.7 kcal/mol, respectively. This information can be utilized to design potent, 
economical and non-toxic natural AR inhibitors from natural phenols for the 
therapeutics of diabetic complications.
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Diabetes mellitus (often called as diabetes) is a cluster of metabolic conditions 
due to defect in insulin secretion, insulin action, or both resulting in prolonged 
hyperglycemia and defective metabolism of food. According to etiological 
classification, Type 1 diabetes (also called as insulin dependent diabetes 
mellitus or juvenile-onset diabetes, occurs due to defect in the β-cells of 
pancreas, resulting in lack of insulin) and Type 2diabetes (also called as non-
insulin dependent diabetes mellitus or adult-onset diabetes, occurs due to 
defect in insulin action)are two most important types of diabetes (American 
Diabetes Association, 2014; Grewal et al., 2014). As per the latest data from 
International Diabetes Federation, in 2013 there were 382 million diabetic 
patients, and in 2035 the number of diabetic patients may approach 600 million. 
Diabetes is the major contributor to the mortality worldwide, especially 
in the developing countries and the latest figures pointed out diabetes as a 
key obstacle in the overall development worldwide. Diabetes has become 
the major health problem worldwide, and has been pointed out as crucial 
importance in community health due to various complications linked with 
it(International Diabetes Federation, 2013; Wild et al., 2004; Olokoba et al., 
2012; Mohan & Anbalagan, 2013). The main effect of lack of insulin or insulin 
resistance is the defective metabolism of glucose in the cells of body resulting 
in increased glucose concentration in blood, and increased metabolism of 
fats and proteins(Kohei, 2010). The diabetic complication result due to long-
lasting increased blood glucose levels resulting in injury to blood vessels 
and peripheral nerves. The major diabetic complications are classified as 
microvascular (diabetic neuropathy, nephropathy, retinopathy, and cataracts) 
and macro vascular complications (defects in cardiovascular and cerebro-
vascular system) (Cade, 2008). The various mechanisms had been proposed 
for diabetic complications including polyol pathway, larger production of 
advanced glycation end products, augmented production of diacylglycerol due 
to hyperglycemia, altered catabolism of extra glucose through hexosamine 
pathway and defect in antioxidant mechanism due to hyperglycemia. The 
polyol pathway is the most accepted mechanism of crucial significance for the 
pathogenesis of complications of diabetes. The activated polyol pathway leads 
to enlarged buildup of sorbitol in cells causing osmotic tension on the cells 
which harms the proteins of cell membrane via various oxidative mechanisms 
(Forbes& Cooper, 2013).
Aldose Reductase (AR) is a member of the aldo-ketoreductase super-
family of enzymes which catalyzes the formation of sorbitol from glucose, the 
very first and most important rate-determining reaction of the polyol pathway 
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(Yabe-Nishimura, 1998; Oates, 2008). Under normal conditions glucose is 
catabolized via glycolysis and Kreb’s cycle leading to formation of building 
blocks and energy for cellular functions. 
In case of hyperglycemia, higher glucose concentration stimulates 
AR resulting in metabolism of glucose by activated polyol pathway. AR 
reduces that glucose to sorbitol, which is later oxidized to fructose. In the 
process of reducing high intracellular glucose to sorbitol, AR consumes 
the cofactor NADPH (an important co-factor involved in production of 
an important antioxidant, glutathione, resulting in decreased glutathione 
levels). Osmotic stress due to accumulation of extra sorbitol and oxidative 
stress due to decrease in NADPH/NADP+ ratio and reduced NAD+leads to 
reduced cellular antioxidant capacity. Increased production of sorbitol 
catalyzed by AR in polyol pathway accumulates in cells and is difficult to 
diffuse through the cell membranes, which increases osmotic stress to cells 
leading to the development of diabetic complications. The accumulation of 
sorbitol through increased activity of AR in lens, retina, and sciatic nerves 
result in retinopathy, neuropathy, and nephropathy, respectively (Forbes& 
Cooper, 2013; Brownlee, 2001; Chung & Chung, 2005). The polyol pathway 
can be targeted by inhibiting the enzyme AR resulting in the reversal of the 
osmotic stress caused by activated polyol pathway. Thus, reduction of the 
polyol pathway by AR inhibitors has been a potential therapeutic target in the 
treatment and prevention of diabetic complications. Numerous AR inhibitors 
have been advanced as drug candidates for the treatment and prevention of 
diabetic complications (Oates, 2008; Brownlee, 2001; Suzen & Buyukbingol, 
2003; Cumbie & Hermayer, 2007).The AR inhibitors developed vary 
structurally including carboxylic acid derivatives, spirohydantoins and related 
cyclic amides, nitromethane derivatives, sulfonamides, thiazolidinediones, 
benzodiazepines, and phenolic derivatives (related to benzopyran-4-one and 
chalcone). Even though numerous clinical trials for the treatment of diabetic 
complications have been conducted over the past two decades with synthetic 
compounds, pharmacokinetic problems connected to these AR inhibitors, 
together with the length of trials, have resulted in the lack of observed efficacy 
(Jain et al., 2012; Grewal et al., 2016). Among these AR inhibitors, epalrestat is 
the only commercially available inhibitor till date. Thus, there is still an urgent 
need for new and safe AR inhibitors. Several potent inhibitors of AR from 
natural sources have been reported which are obtained from terrestrial, micro-
organism, and marine sources for their role in the treatment and prevention 
of diabetic complications. AR inhibitors obtained from natural sources 






derivatives, and vitamin C (Grewal et al., 2016; Fuente & Manzanaro, 2003; 
Nakai et al., 1985).Numerous flavonoids like rutin, kaempferol, quercetin, 
and quercetrin had shown excellent anti-diabetic potential by AR inhibition 
(Lee et al., 2015; Zhang et al., 2016). Some natural phenolic compounds 
were chosen for the docking study from the recent literaturehaving potent 
AR inhibitory activity including nepetin (Tomás-Barberán et al, 1986), 
epicatechingallate (Murara et al., 1994), Capillarisin (Okada et al., 1995), 
isorhamnetin-3,7-disulfate (Haraguchi et al., 1996), Luteolin (Yoshikawa 
et al., 1999), Protocatechualdehyde (Goodarzi et al., 2006), Davidigenin 
(Logendra et al., 2006), curcumin (Muthenna et al., 2009), 2-(4-hydroxy-3-
methoxyphenyl)ethanoic acid (Kato et al., 2006), Quercetin (Chethan et al., 
2008), butein (Lee at al., 2008), desmethylanhydroicaritin (Jung et al., 2008) 
and semilicoisoflavone B (Lee et al., 2010). 
The aim of this study is the in silico evaluation of selected natural phenolic 
compounds in order to establish the structural basis of their AR inhibitory 
activity and to investigate the binding modes of the selected compounds in 
active site of AR to design safer natural drugs as alternatives to synthetic drugs 
using molecular docking. 
2. EXPERIMENTAL
Molecular docking was performed for the selected natural phenolic compounds 
in the binding site of AR protein in AutoDockVina (Trott & Olson, 2010) and 
the graphical user interface, AutoDock Tools (Morris et al., 2009) installed on 
Windows 7 computer. 
2.1 Preparation of Ligand Molecules
The 2-D chemical structures of the ligands were prepared by MarvinSketch 
(Marvin 15.9.21, 2015, ChemAxon) and converted to 3-D by Frog2 server based 
on a graph decomposition of the compounds coupled with an identification of 
the stereo-centres for which the chirality is unspecified (Miteva et al., 2010). 
The ligands were converted to PDBQT files from MOL format using AutoDock 
Tools. 
2.2 Preparation of Protein Molecule
After assessing a numbers of co-crystallized structures of AR protein available 
in the RCSB protein data bank (http://www.rcsb.org/pdb), the best ligand 
bound complexes (PDB entry: 4LBS) was selected with complexes having 
maximum resolution and best binding interactions between ligands and 
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proteins. The PDB files of the target protein was edited using PyMOL (The 
PyMOL Molecular Graphics System, Version 1.7.4.5 Edu, Schrödinger, LLC.) 
by removing complexed inhibitor, all the water molecules as well as all non-
interacting ions. The PDBQT file of AR proteins was generated from the PDB 
files using AutoDock Tools and all the polar hydrogen atoms were added to the 
protein molecule. 
2.3 Preparation of Configuration Files
The “Grid” of AutoDock Tools was used for calculating the grid parameters 
and all the data regarding target protein, ligand, grid size and geometry were 
saved in TXT file. The grid size was set to 32 × 32 × 32 xyz points with grid 
spacing of 0.375 Å and grid center was designated at dimensions (x, y, and z): 
9.568, 0.111, and 0.097. The exhaustiveness was set at 8 and scoring grid was 
calculated from the ligand structure to reduce the computation time.
2.4 Docking Method
The reference ligand, (2-((4-bromo-2,6-difluorobenzyl)carbamoyl)-5-
chlorophenoxy) acetic acid was docked in the active site of target proteins 
and compared with that of the co-crystallized inhibitor of AR (PDB ligand of 
4LBS) for determining the accuracy of the docking protocol. The prepared 
ligand molecules were docked in the active site of the refined AR model 
utilizing AutoDockVina and scored by using scoring function. The binding 
free energy (ΔG, kcal/mol) for each ligand was reported in log file. PyMOL 
was utilized for the analysis of the binding interactions (including H-bond and 
hydrophobic interactions) of the ligands in the active site of target proteins.
3. RESULTS AND DISCUSSION
The names and chemical structures of the natural phenolic compounds selected 
for the molecular docking study are presented in Table 1 along with their 
source and reported AR inhibitory activity in terms of IC50 value (concentration 
causing 50% inhibition of the AR activity). In silico studies were performed 
to explore the affinity and binding interactions of the selected natural phenolic 
compounds in the active site of AR protein (PDB entry: 4LBS). The reference 
ligand was docked into the active site of AR protein; and the docked reference 
inhibitor of AR produced a similar binding pattern and superposition on the 
binding mode of co-crystallized inhibitor with ΔG of –9.2 kcal/mol validating 






Table 1: Structures of natural phenolic compounds selected for docking study 
with their source and reported AR inhibitory activity.







Obtained from green 
tea (Camellia sinensis) 





















with IC50= 12.70 µM
8 Curcumin Obtained from Curcuma 
longawith IC50= 6.8 µM
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with IC50= 1.8 µM
In this study 13 different natural phenolic compounds were selected for 
molecular docking studies. The drug-likeness properties including molecular 
weight, partition coefficient i.e., log P, hydrogen bond donors i.e., HBD, and 
hydrogen bond acceptors i.e., HBA were computed for the selected natural 
phenols. Most of the compounds selected for in silico studies showed drug-like 
properties as contrived by Lipinski’s rule of five (presented in Table 2). All the 
selected natural phenolic molecules were docked in the active site of human 
AR protein (PDB entry: 4LBS). Most of the compounds showed appreciable 
binding pattern in the active site of AR protein as established by analyzing 
their bonding interactions in terms of H-bond, hydrophobic interactions and 






Table 2: Molecular properties, interacting amino acids, distance and ΔG of 
the selected natural phenolic compounds.
Comp. Mol. Wt.* Log P* HBA* HBD* Interacting amino acid (s)
Distance 
(Å) ΔG
1 316 1.6 7 4 His110, Trp111 3.6, 3.1 –8.6
2 442 3.7 9 7 Tyr48, His110, Trp111 3.2, 2.6, 4.0 –8.9
3 316 2.8 7 3 Tyr48, His110 4.2, 3.2 –8.0
4 475 2.0 11 4 Tyr48, His110, Trp111 3.8, 3.3, 3.0 –8.9
5 286 2.4 6 4 Trp111 3.8 –8.1
6 138 1.2 3 2 Trp111 4.8 –6.0
7 258 3.4 4 3 Tyr48 4.7 –8.5
8 368 4.0 6 2 His110, Trp111 3.2, 3.2 –8.2
9 182 1.1 4 2 Tyr48, His110, Trp111 2.8, 3.1, 2.9 –9.8
10 302 1.7 7 5 Trp111 3.9 –8.1
11 272 3.4 5 4 Tyr48, His110, Trp111 3.2, 2.8, 3.2 –9.7
12 368 4.0 6 4 Trp111 2.9 –7.2
13 352 4.2 6 3 Trp111 3.3 –7.3
*Mol. Wt., Log P, HBA, and HBD were calculated using MarvinSketch (2015). 
Based on the lowest docking free energy and better binding interactions in 
the active site of AR protein, compounds 2, 4, 9, and 11 were further analyzed 
in details by PyMOL. The receptor-ligand complexes produced after docking 
of the selected natural phenolic compounds were analyzed in terms of H-bond 
interactions, hydrophobic interactions, binding free energy and orientation 
of the docked compounds in the active site of AR protein. These parameters 
show a chief role in the biological activity of a compound. The docked poses 
of the natural phenolic compounds were ranked based on the docking scores 
i.e. the lowest binding free energy and only the top ranked and best fitted 
conformations of the selected natural phenolic compounds were analyzed for 
the study. The overlay of the selected compounds (2, 4, 9, and 11) with that of 
reference inhibitor in the binding site of AR showed similar binding mode as 
that of the reference ligand (Figure 1). 
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Figure 1: Overlay of compounds (black)2 (a), 4 (b), 9 (c) and 11 (d) with PDB 
ligand 4LBS (grey) in the binding site of AR protein.
 
 
Figure 2: Docked pose showing H-bond interactions for the compounds 2 (a), 






The docked pose of compound 2 showed the H-bond interactions between 
the phenolic OH of compound 2 and OH of Tyr48, NH of His110 and NH of 
Trp111 in binding site of AR protein with H-bond distance of 3.2, 2.6 and 4.0 Å 
respectively (Figure 2a). The docked pose of compound 4 showed the H-bond 
interactions between the alcoholic OH and OH of Tyr48, NH of His110 and 
NH of Trp111 in binding site of AR protein with H-bond distance of 3.8, 3.3 
and 3.0 Å respectively (Figure 2b). The docked pose of compound 9 showed 
the H-bond interactions between the carbonyl and OH of Tyr48, NH of His110 
and NH of Trp111 in binding site of AR protein with H-bond distance of 2.8, 
3.1 and 2.9 Å respectively (Figure 2c). The docked pose of compound 11 
showed the H-bond interactions between the phenolic OH and OH of Tyr48, 
NH of His110 and NH of Trp111 in binding site of AR protein with H-bond 
distance of 3.2, 2.8 and 3.2 Å respectively (Figure 2d). This demonstrates 
that the selected natural phenolic compounds possess the functional groups 
required for effective binding with the active site residues when compared with 
the standard PDB ligand.
The best binding affinity of AR protein was found with the compounds 9 
(2-(4-hydroxy-3-methoxyphenyl)ethanoic acid) and 11 (butein) in the complex 
of AR with binding free energy of -9.8 kcal/mol and -9.7 kcal/mol, respectively. 
Other natural phenolic compoundssuch as compounds 2 (epicatechingallate) 
and 4 (isorhamnetin-3,7-disulfate) also represent good binding affinity with 
AR protein as indicated in Table 2. All these docking results and overlay of 
docked natural phenols with the PDB ligand 4LBS revealed that the selected 
natural phenols have a potential to inhibit AR enzyme.
4. CONCLUSION
Molecular docking studies using AutoDock vina and AutoDock Tools was 
performed to explore the binding mechanism of the selected natural phenolic 
compounds with AR enzyme. In the present molecular modeling study, results 
clearly demonstrated that the selected natural phenolic compounds have a 
similar binding sites and interactions with AR as those of the synthetic drug 
taken for the study and prove that dietary flavonoids (phenolic compounds) 
may possess properties useful for the control of diabetic complications. Thus 
in silico study is actually an added advantage to screen the AR inhibition 
and natural phenolic compounds may serve as useful leads for the synthesis 
of clinically useful and safe inhibitors of AR for therapeutics of diabetic 
complications. The results of docking study revealed that 2-(4-hydroxy-3-
methoxyphenyl)ethanoic acid and 11 (butein) have strongest binding with 
the AR protein with binding free energy of –9.8 kcal/mol and -9.7 kcal/mol, 
respectively. Structural modifications and further studies on these natural 
Molecular Docking 








phenolic compounds are required to develop safe and potent AR inhibitors for 
the management of various diabetic complications. 
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